EcoDrugPlus

Toll-Like Receptor 2 Type-2

Ensembl ID : ENSXMAG00000008258
Gene Symbol: LOC102226787
3 Cross references
206 Possible Orthologues:

Trace Amine Associated Receptor 1

Ensembl ID : ENSXMAG00000027017
Gene Symbol: TAAR1
3 Cross references
391 Possible Orthologues:

Trace Amine Associated Receptor 1

Ensembl ID : ENSXMAG00000026419
Gene Symbol: TAAR1
1 Cross references
416 Possible Orthologues:

Trace Amine Associated Receptor 1

Ensembl ID : ENSXMAG00000023441
Gene Symbol: TAAR1
1 Cross references
391 Possible Orthologues:

Trace Amine Associated Receptor 1

Ensembl ID : ENSXMAG00000029045
Gene Symbol: TAAR1
1 Cross references
386 Possible Orthologues:

Trace Amine Associated Receptor 1

Ensembl ID : ENSXMAG00000026574
Gene Symbol: TAAR1
1 Cross references
416 Possible Orthologues:

Trace Amine Associated Receptor 1

Ensembl ID : ENSXMAG00000020323
Gene Symbol: TAAR1
3 Cross references
417 Possible Orthologues:

Trace Amine Associated Receptor 1

Ensembl ID : ENSXMAG00000023827
Gene Symbol: TAAR1
1 Cross references
385 Possible Orthologues:

Trace Amine Associated Receptor 1

Ensembl ID : ENSXMAG00000027522
Gene Symbol: TAAR1
1 Cross references
364 Possible Orthologues:

Transcription Factor P65-Like

Ensembl ID : ENSXMAG00000011436
Gene Symbol: LOC102219636
3 Cross references
199 Possible Orthologues:

Transient Receptor Potential Cation Channel Subfamily A Member 1

Ensembl ID : ENSXMAG00000010334
Gene Symbol: TRPA1
3 Cross references
200 Possible Orthologues:

Tryptophan 5-Hydroxylase 1-Like

Ensembl ID : ENSXMAG00000001087
Gene Symbol: LOC102234879
3 Cross references
176 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).